RU2005133093A - Соединения для лечения флавивирусных инфекций - Google Patents
Соединения для лечения флавивирусных инфекций Download PDFInfo
- Publication number
- RU2005133093A RU2005133093A RU2005133093/04A RU2005133093A RU2005133093A RU 2005133093 A RU2005133093 A RU 2005133093A RU 2005133093/04 A RU2005133093/04 A RU 2005133093/04A RU 2005133093 A RU2005133093 A RU 2005133093A RU 2005133093 A RU2005133093 A RU 2005133093A
- Authority
- RU
- Russia
- Prior art keywords
- independently
- another
- hydrogen
- pharmaceutically acceptable
- optionally substituted
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims 44
- 150000001875 compounds Chemical class 0.000 title claims 10
- 206010057199 Flaviviral infections Diseases 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 150
- 239000001257 hydrogen Substances 0.000 claims 132
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 132
- 229910052794 bromium Inorganic materials 0.000 claims 72
- 229910052801 chlorine Inorganic materials 0.000 claims 72
- 239000003937 drug carrier Substances 0.000 claims 72
- 150000002148 esters Chemical class 0.000 claims 72
- 229910052731 fluorine Inorganic materials 0.000 claims 72
- 238000000034 method Methods 0.000 claims 70
- 208000015181 infectious disease Diseases 0.000 claims 60
- 125000002252 acyl group Chemical group 0.000 claims 54
- 125000000217 alkyl group Chemical group 0.000 claims 54
- 239000000651 prodrug Substances 0.000 claims 54
- 229940002612 prodrug Drugs 0.000 claims 54
- 150000003839 salts Chemical class 0.000 claims 54
- 230000001225 therapeutic effect Effects 0.000 claims 54
- 239000002777 nucleoside Substances 0.000 claims 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 44
- 229910052760 oxygen Inorganic materials 0.000 claims 42
- 229910052717 sulfur Inorganic materials 0.000 claims 42
- 239000002904 solvent Substances 0.000 claims 36
- 230000002265 prevention Effects 0.000 claims 35
- -1 β-D nucleoside Chemical class 0.000 claims 35
- 241000710781 Flaviviridae Species 0.000 claims 30
- 241000700605 Viruses Species 0.000 claims 30
- 230000002159 abnormal effect Effects 0.000 claims 27
- 230000004663 cell proliferation Effects 0.000 claims 27
- 201000010099 disease Diseases 0.000 claims 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 27
- 125000003342 alkenyl group Chemical group 0.000 claims 24
- 229940024606 amino acid Drugs 0.000 claims 24
- 150000001413 amino acids Chemical class 0.000 claims 24
- 125000003710 aryl alkyl group Chemical group 0.000 claims 24
- 125000003118 aryl group Chemical group 0.000 claims 24
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 24
- 239000001177 diphosphate Substances 0.000 claims 24
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 24
- 235000011180 diphosphates Nutrition 0.000 claims 24
- 125000000262 haloalkenyl group Chemical group 0.000 claims 24
- 125000001188 haloalkyl group Chemical group 0.000 claims 24
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 24
- 150000004712 monophosphates Chemical class 0.000 claims 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 24
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 24
- 239000001226 triphosphate Substances 0.000 claims 24
- 235000011178 triphosphate Nutrition 0.000 claims 24
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 24
- 150000003904 phospholipids Chemical class 0.000 claims 23
- 239000003814 drug Substances 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 18
- 150000002367 halogens Chemical class 0.000 claims 18
- 238000004519 manufacturing process Methods 0.000 claims 18
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 18
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 239000003085 diluting agent Substances 0.000 claims 17
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 12
- 229910052711 selenium Inorganic materials 0.000 claims 12
- 238000011321 prophylaxis Methods 0.000 claims 8
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2s)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 claims 5
- 239000002775 capsule Substances 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 238000007911 parenteral administration Methods 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 230000000699 topical effect Effects 0.000 claims 3
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- RKZDOZOBLOFAIG-ZYLYKRSNSA-N C/C(/C(N)=O)=C(\C(\C(C12)(C1O)O[C@H](CO)C2O)=N/N)/O Chemical compound C/C(/C(N)=O)=C(\C(\C(C12)(C1O)O[C@H](CO)C2O)=N/N)/O RKZDOZOBLOFAIG-ZYLYKRSNSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45863503P | 2003-03-28 | 2003-03-28 | |
| US60/458,635 | 2003-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005133093A true RU2005133093A (ru) | 2006-07-27 |
Family
ID=33098273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005133093/04A RU2005133093A (ru) | 2003-03-28 | 2004-03-29 | Соединения для лечения флавивирусных инфекций |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050049204A1 (https=) |
| EP (1) | EP1626692A4 (https=) |
| JP (1) | JP2006524227A (https=) |
| CN (1) | CN1980678A (https=) |
| AU (1) | AU2004224575A1 (https=) |
| BR (1) | BRPI0408846A (https=) |
| CA (1) | CA2529311A1 (https=) |
| MX (1) | MXPA05010419A (https=) |
| RU (1) | RU2005133093A (https=) |
| WO (1) | WO2004084796A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| KR20080021797A (ko) | 2000-05-26 | 2008-03-07 | 이데닉스(케이만)리미티드 | 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물 |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| PL374781A1 (en) | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| HUE033832T2 (en) | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation |
| RU2005121904A (ru) | 2002-12-12 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | Способ получения 2`-разветвленных нуклеозидов |
| US20090270431A1 (en) * | 2005-10-19 | 2009-10-29 | The University Of Georgia Research Foundation | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections |
| BRPI0715714A2 (pt) * | 2006-08-25 | 2014-03-11 | Wyeth Corp | Métodos para diminuir a frequência de emergência de uma infecção viral de hepatite c resistente ao tratamento, para atrasar a emergência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir o nível de resistência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir a emergência de uma infecção viral de hepatite c resistente a hcv-796, para identificar um indivíduo com uma probabilidade diminuída de responder a uma terapia viral anti-hepatite c, para monitorar, diagnosticar ou prognosticar a infecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar o curso de tratamento de uma infecção viral de hepatite c em um paciente, para prognosticar o desenvolvimento de um ainfecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar a infecção viral de hepatite c em um paciente e para diagnosticar o desenvolvimento de uma infecção viral de hepatite ao tratamento em um paciente |
| CA2663618A1 (en) * | 2006-09-11 | 2008-06-05 | Southern Research Institute | Azole nucleosides and use as inhibitors of rna and dna viral polymerases |
| GB2471806B (en) * | 2008-04-03 | 2012-12-19 | Spring Bank Pharmaceuticals Inc | Compositions and methods for treating viral infections |
| CN102123706B (zh) | 2008-06-17 | 2013-08-14 | 米纳斯吉拉斯联合大学 | 血小板活化因子受体在治疗黄病毒科病毒引起的感染中的用途 |
| WO2014186435A2 (en) | 2013-05-14 | 2014-11-20 | University Of Georgia Research Foundation, Inc. | Compositions and methods for reducing neointima formation |
| US20210353660A1 (en) * | 2018-10-04 | 2021-11-18 | Octagon Therapeutics Inc. | Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs |
| CN114828859A (zh) * | 2019-12-06 | 2022-07-29 | 南京明德新药研发有限公司 | siRNA缀合物、双链siRNA缀合物及其盐和应用 |
| US20230123911A1 (en) * | 2020-01-31 | 2023-04-20 | Octagon Therapeutics, Inc. | Modulation of immune cells |
| WO2021249352A1 (zh) * | 2020-06-10 | 2021-12-16 | 正大天晴药业集团股份有限公司 | 双链siRNA类似物的缀合物 |
| EP4166144A4 (en) * | 2020-06-11 | 2024-07-10 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | DOUBLE-STRANDED SIRNA ANALOGUE CONJUGATE |
| WO2023155909A1 (zh) * | 2022-02-18 | 2023-08-24 | 南京明德新药研发有限公司 | 三氮唑核苷类似物及其作为嵌入基团的应用 |
| CN116808058A (zh) * | 2023-07-25 | 2023-09-29 | 徐州医科大学 | Pyrazofurin在制备治疗戊型肝炎疾病药物中的应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE29835E (en) * | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
| US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US3798209A (en) * | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
| GB1414841A (en) * | 1972-02-11 | 1975-11-19 | Syntex Inc | 2,5-anhydro-dalloses derivatives thereof and c-glycosylnucleosides derived therefrom |
| US3960836A (en) * | 1974-07-22 | 1976-06-01 | Eli Lilly And Company | Acylated derivatives of pyrazofurin and process for their preparation |
| US5102883A (en) * | 1989-10-31 | 1992-04-07 | Du Pont Merck Pharmaceutical Company | Pyrimidine biosynthesis inhibitors useful as immunosuppressive agents |
| ZA931934B (en) * | 1992-03-18 | 1993-03-18 | Us Bioscience | Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals |
| GB9226729D0 (en) * | 1992-12-22 | 1993-02-17 | Wellcome Found | Therapeutic combination |
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
| US6150337A (en) * | 1996-01-23 | 2000-11-21 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes |
| RU2186569C2 (ru) * | 1996-01-23 | 2002-08-10 | Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ | Модуляция экспрессии тн1/тн2 цитокинов рибавирином и аналогами рибавирина в активированных т-лимфоцитах |
| US20020137696A1 (en) * | 1996-01-23 | 2002-09-26 | Robert Tam | Specific modulation of TH1/TH2 cytokine expression by ribavirin in activated T-lymphocytes |
| ATE271063T1 (de) * | 1996-10-16 | 2004-07-15 | Icn Pharmaceuticals | Purin-l-nukleoside, deren analoga und verwendungen |
| IL129126A0 (en) * | 1996-10-16 | 2000-02-17 | Icn Pharmaceuticals | Monocyclic l-nucleosides analogs and uses thereof |
| US6455690B1 (en) * | 1996-10-16 | 2002-09-24 | Robert Tam | L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine |
| US6509320B1 (en) * | 1996-10-16 | 2003-01-21 | Icn Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses thereof |
| EP0948256A4 (en) * | 1996-10-28 | 2007-10-24 | Univ Washington | INDUCTION OF VIRAL MUTATIONS BY INTRODUCTION TO ERROR-CODED RIBONUCLEOSIDE ANALOGUES IN VIRAL RNA |
| US6887707B2 (en) * | 1996-10-28 | 2005-05-03 | University Of Washington | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
| ATE234103T1 (de) * | 1997-12-22 | 2003-03-15 | Schering Corp | Feste, oral verabreichbare ribavirin dosisformen und verfahren zu deren herstellung |
| US6423695B1 (en) * | 1998-01-13 | 2002-07-23 | Ribapharm, Inc. | Cytokine related treatments of disease |
| KR100719606B1 (ko) * | 1998-02-25 | 2007-05-17 | 에모리 유니버시티 | 2'-플루오로뉴클레오사이드 |
| CA2331823A1 (en) * | 1998-05-15 | 1999-11-25 | Schering Corporation | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection |
| US6833361B2 (en) * | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| JP2002527522A (ja) * | 1998-10-16 | 2002-08-27 | シェリング・コーポレーション | 慢性Ｃ型肝炎感染を有する患者における検出可能ＨＣＶ−ＲＮＡ根絶用リバビリン−インターフェロン−α併用療法 |
| MY125300A (en) * | 1999-02-26 | 2006-07-31 | Inst Of Molecular And Cell Biology | Synergistic combination for treatment of viral-mediated diseases |
| US6455508B1 (en) * | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
| US7056895B2 (en) * | 2000-02-15 | 2006-06-06 | Valeant Pharmaceuticals International | Tirazole nucleoside analogs and methods for using same |
| US6495677B1 (en) * | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
| CN1427722A (zh) * | 2000-02-18 | 2003-07-02 | 希拉生物化学股份有限公司 | 用核苷类似物治疗或预防黄病毒感染的方法 |
| EP1964569A3 (en) * | 2000-04-13 | 2009-07-22 | Pharmasset, Inc. | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| KR20080021797A (ko) * | 2000-05-26 | 2008-03-07 | 이데닉스(케이만)리미티드 | 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물 |
| US6815542B2 (en) * | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
| US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| KR20090089922A (ko) * | 2000-10-18 | 2009-08-24 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
| NZ575481A (en) * | 2000-10-18 | 2010-10-29 | Pharmasset Inc | Simultaneous quantification of nucleic acids in diseased cells |
| US7105499B2 (en) * | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| WO2002057425A2 (en) * | 2001-01-22 | 2002-07-25 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| GB0112617D0 (en) * | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| JP2005536440A (ja) * | 2001-09-28 | 2005-12-02 | イデニクス（ケイマン）リミテツド | ４’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物 |
| AU2002330154A1 (en) * | 2001-09-28 | 2003-04-07 | Centre National De La Recherche Scientifique | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| KR20040094692A (ko) * | 2002-02-14 | 2004-11-10 | 파마셋, 리미티드 | 변형된 불소화 뉴클레오사이드 유사체 |
| PL374781A1 (en) * | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| US20040067877A1 (en) * | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
| JP2006507235A (ja) * | 2002-08-01 | 2006-03-02 | フアーマセツト・インコーポレイテツド | フラビウイルス科ウイルス感染治療のためのビシクロ［４．２．１］ノナン系を有する化合物 |
-
2004
- 2004-03-29 RU RU2005133093/04A patent/RU2005133093A/ru not_active Application Discontinuation
- 2004-03-29 AU AU2004224575A patent/AU2004224575A1/en not_active Abandoned
- 2004-03-29 CA CA002529311A patent/CA2529311A1/en not_active Abandoned
- 2004-03-29 WO PCT/IB2004/001429 patent/WO2004084796A2/en not_active Ceased
- 2004-03-29 JP JP2006506588A patent/JP2006524227A/ja active Pending
- 2004-03-29 MX MXPA05010419A patent/MXPA05010419A/es not_active Application Discontinuation
- 2004-03-29 BR BRPI0408846-8A patent/BRPI0408846A/pt not_active IP Right Cessation
- 2004-03-29 US US10/812,448 patent/US20050049204A1/en not_active Abandoned
- 2004-03-29 EP EP04724085A patent/EP1626692A4/en not_active Withdrawn
- 2004-03-29 CN CNA2004800117467A patent/CN1980678A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1626692A4 (en) | 2008-12-10 |
| EP1626692A2 (en) | 2006-02-22 |
| CN1980678A (zh) | 2007-06-13 |
| BRPI0408846A (pt) | 2006-07-04 |
| MXPA05010419A (es) | 2006-05-31 |
| JP2006524227A (ja) | 2006-10-26 |
| CA2529311A1 (en) | 2004-10-07 |
| US20050049204A1 (en) | 2005-03-03 |
| AU2004224575A1 (en) | 2004-10-07 |
| WO2004084796A3 (en) | 2006-04-06 |
| WO2004084796A2 (en) | 2004-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005133093A (ru) | Соединения для лечения флавивирусных инфекций | |
| KR100598474B1 (ko) | 항종양제 | |
| MXPA05005379A (es) | Tioureas de arilo sustituidas y compuestos relacionados; inhibidores de duplicacion viral. | |
| JP2006524227A5 (https=) | ||
| TW200600492A (en) | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | |
| JP2011525171A5 (https=) | ||
| RU2008139195A (ru) | Замещенные арилсульфанамиды как противовирусные средства | |
| RU2007116858A (ru) | Тиазолилдигидроиндазолы | |
| RU2007102281A (ru) | 5-аза-7-деазапуриновые производные для лечения заболеваний, связанных с flaviviridae | |
| UA92746C2 (en) | Thiazole compounds and methods of use | |
| ES2606855T3 (es) | Fosfaplatinos y su uso para el tratamiento de cánceres | |
| RU2000102359A (ru) | Фармацевтическая композиция, обладающая улучшенным противораковым действием и/или сниженными побочными эффектами, содержащая противораковый агент и производное гидроксамовой кислоты | |
| US12325705B2 (en) | Small molecules for the treatment of primary cancer and cancer metastasis | |
| RU2010154173A (ru) | Режим введения нитрокатехолов | |
| RU2001113268A (ru) | Сочетанная терапия рибавирином и интерфероном α для удаления определяемой рнк вируса гепатита с у пациентов с хроническим гепатитом с | |
| HUP0500871A2 (hu) | 5-Ariltetrazol-vegyületek, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| JP2011518168A5 (https=) | ||
| KR101838764B1 (ko) | (ｅ)-4-카복시스티릴-4-클로로벤질설폰의 개선된 안정한 수성 제형 | |
| RU2002101622A (ru) | Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом | |
| AU2008236994A1 (en) | Method of treating melanoma | |
| RU2004126637A (ru) | Производные порфиринплатины, терапевтические активное соединение для получения средства для лечения опухолей, лекарственное средство и способ получения указанного средства | |
| ES2552734T3 (es) | Compuestos para usar en el tratamiento del cáncer | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| RU2008138165A (ru) | Стероидные соединения в качестве ингибиторов стероидсульфатазы | |
| EA005400B1 (ru) | Комбинация на основе производного камптотецина и комбретастатина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080312 |